Multiple Myeloma: Comparing Treatment Options

Multiple myeloma is a cancer of plasma cells. Plasma cells are a type of white blood cell made in your bone marrow. There is no single "best" treatment. Your team chooses from several drug types. Some patients also get a stem cell transplant. The choice depends on your age, your fitness, and how your myeloma behaves. This page lays out the main options side by side. Use it to ask sharper questions.

Some people are diagnosed before myeloma causes any problems. For this group, the standard approach is watchful waiting. That means regular blood tests and monitoring, without starting treatment right away. This is not neglect. Starting powerful drugs before they are needed adds side effects without proven benefit for many people in this group. Ask your team how often you will be monitored. Also ask what change would prompt starting treatment.

Proteasome inhibitors — bortezomib, carfilzomib, and ixazomib block a process cancer cells use to clear out damaged proteins. The proteins build up until the cell dies.

Monoclonal antibodies — daratumumab and elotuzumab are lab-made immune proteins. They attach to myeloma cells and help your immune system destroy them.

Immunomodulators — thalidomide, lenalidomide, and pomalidomide boost immune activity against myeloma cells.

Corticosteroids — steroids have a direct anti-tumor effect in myeloma. They are usually combined with other drug classes, not used alone.

BCL2 inhibitor — venetoclax blocks a protein that helps some myeloma cells survive. This makes them more sensitive to other treatment. NCI describes it as being studied for myeloma that has come back or stopped responding, so it is not a standard part of first treatment.

Most people get a combination of three of these drug types at once. Combining classes that attack myeloma differently tends to work better than any single drug.

Say you are younger and fit enough to handle it. Your team may then recommend high-dose chemotherapy, followed by a stem cell transplant. The transplant uses your own stem cells, collected beforehand. Doctors call this step consolidation. It follows an early period of combination drug therapy called induction. Older or less fit patients often do just as well long-term on drug combinations alone, without transplant. This is a decision to make with your specific health picture in mind. It is not a default step for everyone.

For myeloma that has come back after other treatments, CAR T-cell therapy is an option at some centers. Your own T cells, a type of immune cell, are collected. They are modified in a lab to better recognize myeloma cells. Then they are put back into your body. This process takes more steps than standard chemotherapy. It is generally reserved for relapsed or hard-to-treat disease.

After induction, and transplant if you have one, many people continue on lower-intensity maintenance therapy. This helps keep the myeloma in remission longer. It often uses an immunomodulator, sometimes with a proteasome inhibitor or corticosteroid. Maintenance is usually easier to handle than induction. But it is still real treatment, with its own side effects worth discussing.

Multiple myeloma often responds well to treatment at first. It tends to return, though. If this happens, your team has options. They can switch to a different drug combination. They can try a class you have not used yet. If enough time has passed, they can also use a treatment that worked well before. Relapse is common with myeloma. It does not mean your options are used up.

• Which drug combination are you recommending for me, and why this one over others?
• Am I a candidate for stem cell transplant, and what would that involve?
• What side effects should I expect from my specific combination, and which need a same-day call?
• If this treatment stops working, what would we try next?

• National Cancer Institute — Multiple Myeloma and Other Plasma Cell Neoplasms Treatment (PDQ)